welcome
Investor's Business Daily

Investor's Business Daily

Business

Business & Economics

Top-Notch Biotech Hits Record High After Trouncing Quarterly Calls

Investor's Business Daily
Summary
Nutrition label

81% Informative

Exelixis stock shot up 20.8% to 44.65 on Wednesday .

The biotech leader trounced first-quarter expectations and raised its 2025 sales outlook by $100 million .

The company is best known for Cabometyx , a treatment for a form of kidney cancer called renal cell carcinoma, or RCC .

In March , the Food and Drug Administration approved the drug for pancreatic neuroendocrine tumors.

VR Score

83

Informative language

85

Neutral language

14

Article tone

formal

Language

English

Language complexity

52

Offensive language

not offensive

Hate speech

not hateful

Attention-grabbing headline

not detected

Known propaganda techniques

not detected

Time-value

short-lived

Affiliate links

no affiliate links